BACKGROUND: Our aim was to use quantitative real-time PCR (Q-PCR) and RNA expression profiles (RNA-EPs) to investigate HER2 status in relation to outcome. PATIENTS AND METHODS: Cut-off levels for Q-PCR and RNA-EP were established in relation to immunohistochemistry (IHC) validated by FISH in a test set of frozen tissue samples from 40 primary breast cancers. The HER2 status was subsequently studied in another validation set of 306 tumors, where Q-PCR and RNA-EP results were compared with previously carried out IHC that we had validated by chromogenic in situ hybridization (CISH). RESULTS: Q-PCR and RNA-EP offered similar sensitivity (90% versus 77%), specificity (93% versus 95%), and negative (99% versus 98%) and positive (63% versus 61%) predictive values for HER2 determinations. Analyses of relapse-free survival (RFS) and overall survival on the basis of 5 and 10 years of follow-up indicated equivalent hazard ratios for all three techniques. In contrast to IHC/CISH, both Q-PCR and RNA-EP analyses of HER2 also gave statistically significant results regarding RFS and breast cancer-corrected survival after 10 years of follow-up. CONCLUSION: The use of RNA-EP and Q-PCR to analyze HER2 in frozen and formalin-fixed breast cancer samples may be an alternate approach to IHC in combination with FISH/CISH.
BACKGROUND: Our aim was to use quantitative real-time PCR (Q-PCR) and RNA expression profiles (RNA-EPs) to investigate HER2 status in relation to outcome. PATIENTS AND METHODS: Cut-off levels for Q-PCR and RNA-EP were established in relation to immunohistochemistry (IHC) validated by FISH in a test set of frozen tissue samples from 40 primary breast cancers. The HER2 status was subsequently studied in another validation set of 306 tumors, where Q-PCR and RNA-EP results were compared with previously carried out IHC that we had validated by chromogenic in situ hybridization (CISH). RESULTS: Q-PCR and RNA-EP offered similar sensitivity (90% versus 77%), specificity (93% versus 95%), and negative (99% versus 98%) and positive (63% versus 61%) predictive values for HER2 determinations. Analyses of relapse-free survival (RFS) and overall survival on the basis of 5 and 10 years of follow-up indicated equivalent hazard ratios for all three techniques. In contrast to IHC/CISH, both Q-PCR and RNA-EP analyses of HER2 also gave statistically significant results regarding RFS and breast cancer-corrected survival after 10 years of follow-up. CONCLUSION: The use of RNA-EP and Q-PCR to analyze HER2 in frozen and formalin-fixed breast cancer samples may be an alternate approach to IHC in combination with FISH/CISH.
Authors: Isabell D Witzel; Karin Milde-Langosch; Ralph M Wirtz; Claudia Roth; Maike Ihnen; Sven Mahner; Christine Zu Eulenburg; Fritz Jänicke; Volkmar Müller Journal: J Cancer Res Clin Oncol Date: 2010-03-04 Impact factor: 4.553
Authors: Ayuko A Iverson; Cheryl Gillett; Paul Cane; Christopher D Santini; Thomas M Vess; Lauren Kam-Morgan; Alice Wang; Marcia Eisenberg; Charles M Rowland; Janice J Hessling; Samuel E Broder; John J Sninsky; Andrew Tutt; Steven Anderson; Sheng-Yung P Chang Journal: J Mol Diagn Date: 2009-03 Impact factor: 5.568
Authors: Ulrich Andergassen; Simone Hofmann; Alexandra C Kölbl; Christian Schindlbeck; Julia Neugebauer; Stefan Hutter; Verena Engelstädter; Matthias Ilmer; Klaus Friese; Udo Jeschke Journal: Int J Mol Sci Date: 2013-01-08 Impact factor: 5.923
Authors: Fabíola E Rosa; Sara M Silveira; Cássia G T Silveira; Nádia A Bérgamo; Francisco A Moraes Neto; Maria A C Domingues; Fernando A Soares; José R F Caldeira; Silvia R Rogatto Journal: BMC Cancer Date: 2009-03-23 Impact factor: 4.430
Authors: A K Koutras; K T Kalogeras; M-A Dimopoulos; R M Wirtz; U Dafni; E Briasoulis; D Pectasides; H Gogas; C Christodoulou; G Aravantinos; G Zografos; E Timotheadou; P Papakostas; H Linardou; E Razis; T Economopoulos; H P Kalofonos; G Fountzilas Journal: Br J Cancer Date: 2008-11-04 Impact factor: 7.640
Authors: G Viale; L Slaets; J Bogaerts; E Rutgers; L Van't Veer; M J Piccart-Gebhart; F A de Snoo; L Stork-Sloots; L Russo; P Dell'Orto; J van den Akker; A Glas; F Cardoso Journal: Ann Oncol Date: 2014-04 Impact factor: 32.976
Authors: Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes Journal: Arch Pathol Lab Med Date: 2013-10-07 Impact factor: 5.534